TVI-Brain-1 is under clinical development by TVAX Biomedical and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TVI-Brain-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TVI-Brain-1 overview
TVI-Brain-1 is under development for the treatment of recurrent grade 4 astrocytoma (glioblastoma multiforme) and glioblastoma multiforme. The therapeutic candidate is administered as intravenous infusion. It is developed based on TVAX immunotherapy platform that employs a unique combination of cancer cell vaccination and killer T-cell treatment.
It was in pediatrics for the treatment of high grade glioma.
TVAX Biomedical overview
TVAX Biomedical is a company that develops drugs in the clinical stage cell-based on immunotherapy for treatment of cancer. It uses proprietary combination of cancer cell vaccination with killer T cell treatment. The company’s TVI-Brain-1 is a drug therapy used for the treatment of brain cancer. TVAX Biomedical is also developing therapy for treatment of kidney cancer. The company conducts clinical trials in key canine cancers to determine safety and usefulness of TVAX Immunotherapy as a treatment for wide range of canine cancer types. It also undertakes clinical trials for TVI-Kidney-1 to support its potential FDA approval. TVAX Biomedical is headquartered in Olathe, Kansas, the US.
For a complete picture of TVI-Brain-1’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
